Revenue
2019
2020
2021
2022
2023
2024
2025
Korro Bio, Inc. (KRRO)
Price$13.06Cached quote
Net income
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.4M | $2.3M | $0 | $0 | $14.1M | $37.0M | $28.9M | — | — |
| Research & development | $65.6M | $63.6M | $57.3M | $42.2M | $60.9M | $37.4M | $18.8M | $11.9M | $12.0M |
| Operating expenses | $128.2M | $94.2M | $84.5M | $59.0M | $98.1M | $64.5M | $49.6M | $18.9M | $16.3M |
| Operating income | −$121.9M | −$91.9M | −$84.5M | −$59.0M | −$84.0M | −$27.6M | −$20.7M | −$18.9M | −$16.3M |
| Operating margin | −1,906.37% | −4,047.12% | — | — | −597.32% | −74.49% | −71.42% | — | — |
| EBITDA | −$117.6M | −$88.3M | −$80.9M | −$56.5M | −$81.3M | −$26.4M | −$19.9M | −$18.3M | −$15.8M |
| EBITDA margin | −1,839.41% | −3,890.14% | — | — | −577.59% | −71.39% | −68.62% | — | — |
| Net income | −$117.3M | −$83.6M | −$81.2M | −$58.0M | −$84.7M | −$26.5M | −$18.7M | −$19.2M | −$20.2M |
| Net profit margin | −1,834.48% | −3,680.36% | — | — | −601.98% | −71.68% | −64.76% | — | — |
| Basic EPSper basic share | -$12.48 | -$9.37 | -$53.08 | -$227.42 | -$2.47 | -$0.82 | -$2.29 | -$12.53 | -$28.79 |
| Diluted EPSper diluted share | -$12.48 | -$9.37 | -$53.08 | -$227.42 | -$2.47 | -$0.82 | -$2.29 | -$12.53 | -$28.79 |
Owners
Reported shareholders
10.46%of listed shares
Lynx1 Capital Management LP1.54M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Lynx1 Capital Management LP | 10.46%1.54M shares |
Nantahala Capital Management, LLC | 8.98%1.32M shares |
SANDELL SCOTT D | ≈8.83%1.3M shares |
BASKETT FOREST | ≈8.83%1.3M shares |
Mathers Edward T | ≈8.83%1.3M shares |
NEA Management Company, LLC | 8.83%1.3M shares |
Walker Paul Edward | ≈8.83%1.3M shares |
Florence Anthony A. Jr. | ≈8.83%1.3M shares |
Behbahani Ali | ≈8.83%1.3M shares |
Makhzoumi Mohamad | ≈8.83%1.3M shares |
Chang Carmen | ≈8.83%1.3M shares |
New Enterprise Associates 17, L.P. / NEA 17 GP, LLC / NEA Partners 17, L.P. | ≈8.83%1.3M shares |
Yang Rick | ≈8.83%1.3M shares |
Venrock Adviser, LLC | 6.86%1.01M shares |
Atlas Venture Life Science Advisors, LLC | 6.55%962.88K shares |
Balyasny Asset Management L.P. | 6.47%951.78K shares |
BlackRock, Inc. | 5.56%817.62K shares |
Affinity Asset Advisors, LLC | 4.81%706.9K shares |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 3.68%540.97K shares |
ADAR1 Capital Management, LLC | 3.67%540.05K shares |
Percentages use 14.71M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Reported positions exceed 100% in total, so the circle shows the selected holder only.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 24, 2026Form 4 · 10b5-1 | FORMELA JEAN FRANCOISDirector | SellCommon Stock · indirect | 114 | $14.98 | $1.7K | 169.6K |
| Jun 24, 2026Form 4 · 10b5-1 | FORMELA JEAN FRANCOISDirector | SellCommon Stock · indirect | 7.0K | $14.60 | $101.9K | 169.7K |
| Jun 24, 2026Form 4 · 10b5-1 | FORMELA JEAN FRANCOISDirector | SellCommon Stock · indirect | 666 | $14.98 | $10.0K | 793.3K |
| Jun 24, 2026Form 4 · 10b5-1 | FORMELA JEAN FRANCOISDirector | SellCommon Stock · indirect | 40.7K | $14.60 | $593.9K | 794.0K |
| Jun 23, 2026Form 4 · 10b5-1 | FORMELA JEAN FRANCOISDirector | SellCommon Stock · indirect | 17.4K | $14.25 | $248.3K | 176.6K |